Jim Simons
LXEO icon

Jim Simons’s Lexeo Therapeutics LXEO Stock Holding History

Jim Simons’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-217,772
Closed -$2.16M – 3510
2025
Q4 		$2.16M Buy
217,772
+68,472
+46% +$625K ﹤0.01% 1814
2025
Q3 		$991K Buy
149,300
+43,100
+41% +$208K ﹤0.01% 2485
2025
Q2 		$427K Buy
106,200
+85,900
+423% +$282K ﹤0.01% 2913
2025
Q1 		$70.4K Buy
+20,300
New +$89.9K ﹤0.01% 3241
2024
Q2 		– Sell
-14,576
Closed -$229K – 3778
2024
Q1 		$229K Buy
+14,576
New +$228K ﹤0.01% 3184

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's LXEO Position: Q1 2026 in Review

Jim Simons sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 217,772 shares — an estimated $2.16M sold.

Jim Simons first reported a position in LXEO in Q1 2024 and held it in 5 quarters. The position peaked at $2.16M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Jim Simons reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 217,772 Lexeo Therapeutics shares in Q1 2026, an estimated $2.16M.
  • Jim Simons first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 5 quarters.
  • Jim Simons's Lexeo Therapeutics position peaked at $2.16M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.